1、Struggling with long R&D cycles and low clinical conversion rates for chronic disease drugs? Customized in vivo efficacy platform accelerates reliable efficacy verification

–Industry Pain Point:

Poor stability in the construction of traditional chronic disease models and limited clinical relevance lead to a disconnect between preclinical data and clinical effects, resulting in high R&D costs and long cycles.

–Value proposition:

Leveraging a multi-species, multi-mechanism chronic disease model platform to provide highly predictive in vivoefficacy data, shortening drug screening cycles by 30% and reducing the risk of clinical failure.

2、Service Overview

Key Bottlenecks and Solutions for Preclinical Efficacy Evaluation of Chronic Disease Drugs

1. Industry positioning: Preclinical efficacy verification of chronic disease drugs (e.g., metabolic, cardiovascular, fibrotic diseases) is a core step for IND filing, yet pathological differences between animal models and the human body often lead to unreliable data.

2. Core pain points:
   • Poor model stability: Such as significant blood glucose fluctuations in diabetic models and insufficient pathological reproducibility in liver fibrosis models.
   • Single endpoint indicators: Reliance on basic biochemical indicators such as blood glucose and liver enzymes, lacking multi-dimensional mechanism verification.

3. Solutions:
   • Improve the clinical relevance of data through standardized chronic disease model construction (e.g., STZ-induced diabetes, CCl4-induced liver fibrosis) combined with multi-dimensional evaluation including imaging, histopathology and molecular detection.
   • Objective: Shorten R&D cycles and reduce the cost of repeated experiments caused by model failure.

3、Our Services

Segmented by disease areas, covering mainstream research needs for chronic disease drug efficacy

4、Technology Platforms and Advantages

Multi-dimensional technical guarantees for data reliability and efficiency

1. Core platforms:
   • Highly predictive model library: Over 50 validated chronic disease models (covering diabetes, NASH, heart failure, etc.) with high clinical pathological relevance (e.g., db/db mice recapitulate the entire progression of T2DM).
   • Imaging-pathology linkage platform:
   • In vivomicroCT for quantitative analysis of visceral/subcutaneous fat.
   • High-frequency cardiac color Doppler ultrasound for real-time monitoring of cardiac function.
   • Quantitative histopathological analysis (e.g., Metavir scoring for liver fibrosis)

2. Infrastructure:
   • SPF-grade animal facility (5,000 cage capacity, ISO environmental certification)
   • Molecular detection platform (ELISA, qPCR, Western blot)
   • Pathology system (fluorescence microscope, chemical gel imager, Image-Pro Plus quantitative analysis system)

3. Differentiated advantages:
   • Cross-species flexibility: Supports rat, mouse and rabbit models to meet different administration requirements for small molecules/biologics.
   • End-to-end data chain: One-stop output from model construction → efficacy detection → mechanism exploration (e.g., inflammatory pathway PCR array).

5、Service Process

• 1. Demand connection (1 working day): Clarify model type, administration scheme and endpoint indicators (e.g., customized PK/PD time points).
• 2. Protocol design (3 working days): Provide IACUC-compliant experimental protocols, including animal quantity, grouping and statistical methods.
• 3. Model construction (2-8 weeks): Weekly updates on model establishment progress (e.g., blood glucose curves for diabetic models).
• 4. Drug administration and monitoring: Supports multiple administration routes such as oral, injection, inhalation and implantable pump, with real-time recording of body weight/behavioral changes.
• 5. Sample collection and analysis:
  In vivo imaging/imaging detection
  Serum/tissue biochemical and molecular detection
  Histopathology (HE/IHC)
• 6. Data delivery (2 weeks): Provision of raw data + statistical reports (GLP-aligned format), including methodological details.
• 7. Project conclusion support: Assistance with data interpretation and support for the writing of the pharmacodynamic section required for IND filing.

6、Quality Control and Compliance

Strict quality control system to ensure data credibility

• Standard compliance: Experimental operations are in line with AAALAC animal welfare guidelines and GLP-aligned specifications (e.g., double-blind sample detection).
• Quality control nodes:
• -Model validation: Positive control groups are set for each batch of animals (e.g., metformin for hypoglycemic validation).
• -Data review: 100% retention of raw data (including pathological sections, flow cytometry plots), supporting third-party audits.
• Qualification documents: Provision of experimental animal use license, SOP for detection methods and sample traceability records.

7、Case Studies

Case 1: In Vivo Efficacy Evaluation of Anti-obesity Drugs

• Client demand: Evaluate the weight loss effect and mechanism of a compound on HFD-induced obese mice.
• Protocol:
• Model: C57 mice fed with HFD for 16 weeks
• Grouping: Model control group, positive drug group (Orlistat), test drug low/high dose groups
• Detection: Body weight curve, microCTfor fat quantification, fasting blood glucose, ELISA for adipokine detection
• Results:
• Body weightsin the test drug groups (vs. model group, P＜01) were significantly reduced, returning to the level of normal mice.
• Epididymal fat weights in the test drug groupswere significantly decreased (vs. model group, P＜01), returning to the level of normal mice.
• View the full report

Case 2: Screening of Anti-liver Fibrosis Drugs

• Model: CCl4-induced liver fibrosis in C57BL/6 mice (8 weeks)
• Key data:
• liver fibrosis scores in the test drug groups (Masson staining)were significantly reduced.
• serum ALTin the test drug groups were significant decreased (vs. model group)
• Download data summary

8、Cooperation Advantages

Why pharmaceutical enterprises choose Jennio-Bio?

• Customized response: Adjust models according to drug characteristics (e.g., diabetic complication models combined with nephropathy).
• Timeliness guarantee: Standard project cycle is 30% faster than the industry average (e.g., 8-week delivery for liver fibrosis efficacy).
• Cost optimization: Shared model library reduces the cost of individual projects, supporting phased payment.
• Global experience: Served more than 10 pharmaceutical enterprises including Roche and Jiangsu Zhengda Tianqing Pharmaceutical, and completed over 100 chronic disease efficacy projects in total.

9、FAQ

Q1: Are non-human primate chronic disease models supported?

A: Not currently supported. We focus on rodent models to optimize cost efficiency, but can collaborate with partner institutions for docking.

Q2: Can report formats meeting FDA filing requirements be provided?

A: Yes. Reports include raw data, statistical methods and QC records, meeting the requirements for Pre-IND documents.

Q3: How to handle model failure?

A: Free rework or proportional refund (clear terms in the contract), with a historical model success rate of >90%.

10、Laboratory Highlights

Showcase of key facilities

• 5,000 cage capacity with independent IVC system
• Quantitative analysis of fat distribution and bone mineral density
• HALO®AI for quantitative fibrosis area analysis

View More

11、Contact Us

Consult Now:

Tel: +86 18802035152

Email: 3691125803@qq.com

Limited-time benefits:

• Free access to Technical White Paper on Chronic Disease Model Construction
• 15% prepayment discount for the first order

Download Service Brochure | Book Technical Evaluation